What Is Thymosin Alpha-1? A Research Guide
- Durham Peptides
- 2 days ago
- 3 min read
Thymosin Alpha-1 is a 28-amino-acid peptide, CAS 62304-98-7, originally isolated from thymic tissue — the gland that trains T-cells during immune development. It is one of the few research peptides with a genuine clinical history behind it rather than only preclinical work, and it is also one of the most reliably confused with a completely different molecule.
The naming problem, first
Thymosin Alpha-1 and Thymosin Beta-4 are not variants of each other. They are unrelated peptides that happen to have been isolated from the same tissue fraction in the 1960s and 70s, and were named by which chromatographic fraction they appeared in rather than by any structural relationship.
Thymosin Alpha-1 | Thymosin Beta-4 (TB-500) | |
|---|---|---|
Length | 28 amino acids | 43 amino acids |
N-terminus | Acetylated | Acetylated |
Primary research area | Immune modulation, T-cell maturation | Actin sequestration, tissue repair, angiogenesis |
Binding partner | Toll-like receptors | G-actin |
Clinical status | Approved in ~35 countries as Zadaxin | No approved indication |
They share a name prefix and an acetylated N-terminus. That is the extent of it. A researcher choosing between them is not choosing a dose or a strength — they are choosing between two entirely different mechanisms.
How Thymosin Alpha-1 is understood to work
The peptide acts on innate immune signalling rather than on a single downstream target. The best-characterised interaction is agonism at Toll-like receptors — TLR2 and TLR9 in particular — on dendritic cells and monocytes. Activating those receptors shifts dendritic cell maturation, which in turn influences how naive T-cells differentiate.
The practical framing in the literature is that Thymosin Alpha-1 does not suppress or stimulate immunity in a single direction. It is described as an immune modulator: in models of immune suppression it tends to restore T-cell responsiveness, while in models of excessive inflammation it has been reported to dampen the response. That bidirectional behaviour is unusual and is the main reason the peptide has held research interest for four decades.
Research history
Thymosin Alpha-1 has been studied in chronic hepatitis B and C, in sepsis, in immune reconstitution during chemotherapy, and as a vaccine adjuvant in elderly populations where response to vaccination is blunted. It is approved and marketed as Zadaxin in roughly 35 countries, though not in Canada or the United States.
That regulatory position is worth understanding correctly. Approval elsewhere means the peptide has passed safety and efficacy review in those jurisdictions for specific indications — it does not mean it is approved here, and material sold by a research supplier in Canada is supplied for laboratory research only.
What the dosage literature describes
Clinical studies of Zadaxin have typically used a fixed subcutaneous dose administered twice weekly over extended courses, rather than weight-scaled dosing. Those figures come from approved-indication protocols in jurisdictions where the drug is licensed, under medical supervision, and they are not a template for anything else.
For laboratory work the controllable variable is concentration. A 10mg vial reconstituted with 2mL of bacteriostatic water yields 5mg/mL; with 5mL, 2mg/mL. Choose the volume that puts your working concentration where the protocol needs it.
Handling and storage
Sealed and lyophilized: 2–8°C protected from light; −20°C for long-term storage.
Reconstitution: bacteriostatic water, sold separately. Add slowly down the vial wall — do not shake, as agitation can denature peptides at the air-liquid interface.
After reconstitution: refrigerated, used within an appropriate research timeframe.
Verification: Janoshik-tested batches carry a unique report key you can confirm independently.
Is Thymosin Alpha-1 the same as TB-500?
No. TB-500 refers to Thymosin Beta-4, a 43-amino-acid peptide studied in tissue repair and angiogenesis through actin binding. Thymosin Alpha-1 is a 28-amino-acid immunopeptide studied in T-cell maturation and Toll-like receptor signalling. They are unrelated molecules that share a naming convention from the era they were isolated.
What are Thymosin Alpha-1's reported effects?
The research literature describes immune modulation rather than a single directional effect — restoration of T-cell responsiveness in immunosuppressed models, and dampening of excessive inflammatory response in others. It has been studied in chronic viral hepatitis, sepsis, and as a vaccine adjuvant.
Is Thymosin Alpha-1 approved anywhere?
Yes, as Zadaxin in approximately 35 countries for specific indications including chronic hepatitis B. It is not approved in Canada or the United States, and research-grade material is supplied for laboratory use only.
Is it available in Canada?
Yes. Durham Peptides stocks Thymosin Alpha-1 10mg domestically, with same-business-day shipping on orders placed and paid before 5:00 PM EST.
